FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	205/19
vvasiliilytuii,	D.C.	20049

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rombotis Spiro George						2. Issuer Name and Ticker or Trading Symbol <u>Cyclacel Pharmaceuticals, Inc.</u> [CYCC]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
					-												er (give title		Other	(specify
(Last) (First) (Middle) 200 CONNELL DRIVE, SUITE 1500						3. Date of Earliest Transaction (Month/Day/Year) 05/21/2013									X Ollicer (give title Other (specify below) President & C.E.O.					
(Street) BERKELEY HEIGHTS NJ 07922						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(St	ate) (Zip)			Person										3				
		Tabl	e I - No	n-Deriv	ative/	Sec	curitie	s Acc	quired,	Dis	posed o	f, oı	r Bene	eficia	ally C)wne	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Seco		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v			Amount		(A) or (D)	Price	, 1	Transaction(s) (Instr. 3 and 4)				(111341.4)			
Common Stock, \$0.001 par value per share 05/2					1/2013	3			P		100,000 A		\$	3	268,292(1)		D)		
		Та									sed of, onvertib				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		ount			9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	of							

Explanation of Responses:

1. The total number of shares of common stock beneficially owned by the Reporting Person has been reduced due to an inadvertent mathematical error in a prior report. Of the shares of common stock reported, 142 shares are held indirectly by Mr. Rombotis through his IRA account and 30,714 shares are represented by unvested restricted stock units.

> 05/22/2013 /s/ Spiro George Rombotis

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.